Brokers Issue Forecasts for ADMA Biologics FY2024 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA) – Stock analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of ADMA Biologics in a research note issued on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn $0.52 per share for the year, up from their prior forecast of $0.50. Cantor Fitzgerald has a “Overweight” rating and a $20.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.52 per share.

Several other research firms have also commented on ADMA. HC Wainwright raised their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Raymond James lifted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Trading Up 2.4 %

NASDAQ ADMA opened at $16.71 on Wednesday. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $19.23 and a two-hundred day simple moving average of $17.23. ADMA Biologics has a 12-month low of $4.82 and a 12-month high of $23.64. The stock has a market cap of $3.95 billion, a P/E ratio of 59.68 and a beta of 0.76.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period last year, the firm earned $0.01 earnings per share.

Insider Activity at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.70% of the stock is currently owned by insiders.

Institutional Trading of ADMA Biologics

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new position in shares of ADMA Biologics during the second quarter worth about $29,000. Hollencrest Capital Management bought a new position in shares of ADMA Biologics during the third quarter worth about $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics during the third quarter worth about $31,000. GAMMA Investing LLC grew its position in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the last quarter. Finally, National Bank of Canada FI bought a new position in shares of ADMA Biologics during the third quarter worth about $35,000. Institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.